Zydus Lifesciences Announces ₹1,100 Crore Share Buyback at ₹1,150/Share

Zydus Lifesciences has approved a share buyback of up to 95.65 lakh equity shares (0.95% of paid-up capital) at ₹1,150 per share, with a total outlay not exceeding ₹1,100 crore. The buyback will be executed via the tender offer route, with May 29, 2026 as the record date for shareholder eligibility. Key Highlights: Purpose: Return surplus capital to shareholders; signals confidence in financial strength and valuation. Financial Impact: Buyback value represents ~5.16% of standalone and ~3.84% of consolidated equity + free reserves (as of March 31, 2026). Eligibility: All shareholders (including promoters) holding shares on the record date may participate on a proportionate basis. Governance: A dedicated Buyback Committee will oversee execution and regulatory compliance. Strategic Context: The buyback reflects Zydus' robust cash flows post-deleveraging and successful product launches. At ₹1,150/share, the offer price implies a modest premium to recent market levels, providing an exit option for investors while optimizing capital structure. $ZYDUSLIFE